Expert Rev Clin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Excessive Nighttime Urination (Nocturnal Polyuria)

Nocturnal polyuria (NP) is the primary cause of nocturia among elderly individuals1. It is characterized by excessive urine production during the night.

Neurourol urodynClin pharmacolPrinceoflove shutterstockDanielle ellisCanadian urological associationInternational continence societyStandardisation sub committeeInternational continenceThink tankCan urol assocUrological associationCentral europeanIntj clinContinence societyExpert rev clinNocturnal polyuria

Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors

Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Falal cosentyx secukinumabCochrane libraryHealth drugRadboud university medical centerInternational psoriasis council juulInternational psoriasis councilRadboud university medical centreSystematic reviewAntagonist receivesModerate to severe plaqueSpec featureFirst selectiveActive psoriatic arthritisExpert rev clin

Nemolizumab Monotherapy Successful in Prurigo Nodularis Patients Becoming Itch-Free

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

Clin pharmacolDermatol venereolNemolizumab monotherapyWorld congressLate breaking phasePublished julyEur acad dermatolExpert rev clin

Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4

ZUG, Switzerland (BUSINESS WIRE) Jul 4, 2023

United statesClin pharmacolChristian marcouxDermatol venereolRachel mooneyChugai pharmaceutical co ltdCorporate communicationsDrug administrationWorld congressGlobal franchise communicationsBreakthrough therapyInjectable aestheticsDermatological skincareEur acad dermatolExpert rev clinUnit ed states

Galderma WCD 2023 LateBreaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of ItchFree Patients by Week 4

Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology WCD in Singapore.

United statesClin pharmacolRachel mooneyChristian marcouxDermatol venereolGlobal franchise communicationsDrug administrationCorporate communicationsWorld congressChugai pharmaceutical co ltdBreakthrough therapyInjectable aestheticsDermatological skincareEur acad dermatolExpert rev clinUnit ed states